Vascular Endothelial Growth Factor Regulates Excitatory Synaptic Transmission in Hippocampal Neurons

Yu-Fei Huang^{1,2}, Chih-Hao Yang¹, Chiuan-Shiou Chiou^{2,3}, Chiung-Chun Huang¹ and Kuei-Sen Hsu^{1,2}

¹Department of Pharmacology, ²Institute of Basic Medical Sciences, and ³Department of Anesthesiology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan

PharmSight on Huang et al., Pharmacological and genetic accumulation of hypoxia-inducible factor- 1α enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor. J Neurosci 2010;30:6080-93.

Abstract

Vascular endothelial growth factor (VEGF), in addition to its essential role in the processes of vascularization and angiogenesis, exerts direct effects on neural cells in the central nervous system. There is abundant evidence indicating that VEGF protects neurons against cell death induced by a variety of insults, including hypoxia/ischemia and seizures. Recent work has demonstrated the expression of VEGF and its receptors in neurons and has revealed that VEGF can act as a neurotrophic factor to regulate neurogenesis and mediate the effects of enriched environment and antidepressants on hippocampal plasticity. Current studies from our laboratory and those of others have found that VEGF can activate divergent signaling components to regulate excitatory synaptic transmission in hippocampal neurons. on Here we present an overview current understanding of cellular and molecular mechanisms by which VEGF signaling is regulated in neural cells and discuss the recent advances in the understanding of how VEGF signaling regulates excitatory synaptic transmission in hippocampal neurons. The role for VEGF in regulating synaptic plasticity will be also discussed in the article.

Keywords: VEGF; Glutamate; Synaptic plasticity; Hippocampus; Neuron

Received 07/30/10; accepted 08/17/10

Vascular endothelial growth factor (VEGF) is a family of basic, heparin-binding, homodimeric glycoproteins that were originally found in the endothelial cells (1) with high potency of angiogenesis (2), vascular permeability (3) and endothelial proliferation (4). The VEGF family includes VEGF-A, placental-derived growth factor (PIGF), VEGF-B, VEGF-C, VEGF-D in mammals and two exogenous VEGF subtypes, virus genomeencoded VEGF (VEGF-E) and snake venom-derived VEGF (VEGF-F) (5). VEGF-A is the protypical member of the VEGF family. Through alternative exon splicing, human VEGF-A gene gives rise to at least six different transcripts, encoding isoforms of 121 (VEGF-A₁₂₀ in mouse), 145, 165 (VEGF-A₁₆₄ in mouse), 183, 189 and 206 amino acid residues (6, 7). VEGF₁₂₁ and VEGF₁₆₅ are secreted in soluble form, while VEGF₁₄₅, VEGF₁₈₉ and VEGF₂₀₆ are bound to cell-surface heparin-containing proteoglycans in the extracellular matrix. VEGF exerts its biological functions via activation of the protein tyrosine kinase receptors, VEGF receptor 1 (VEGFR-1, Flt-1) VEGFR-2 (KDR/Flk-1), and which differ considerably in signaling properties (8). VEGFR-1 and VEGFR-2 are structurally similar, consisting of an extracellular ligand-binding domain with seven immunoglobulin-like domains in the extracellular domain, a single transmembrane region and an intracellular consensus tyrosine kinase domain that is interrupted by a kinase-insert domain (9). Binding by VEGF triggers a rapid tyrosine phosphorylation of the receptors, which in turn allows the receptors to associate with various effector molecules such as the phosphatidylinositol 3-kinase (PI3K), Shc, Grb2, and the phosphatases SHP-1 and SHP-2. In addition, VEGF receptor activation can trigger

Correspondence: Kuei-Sen Hsu, Ph.D., Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Rd, Tainan 701, Taiwan. Tel: 886-6-2353535 ext. 5498. Fax: 886-6-2749296. email: richard@mail.ncku.edu.tw

VEGF subtype	Preparation	Effect	Signaling pathway	Reference
VEGF ₁₆₅	Rat hippocampal	(1) Decrease PS	ND	18
(200 ng/ml)	slices (CA1, CA3 and DG)	(2) Suppress spontaneous burst discharges		
VEGF ₁₆₅	Rat brainstem	(1) Decrease evoked	ND	19
(200 ng/ml)	slices (hypoglossal motor neuron)	potential		
VEGF ₁₆₅	Rat hippocampal	(1) Increase fEPSP slope	VEGFR2/	20
(10 ng/ml)	slices (CA1)	(2) Enhance LTP induction	CaMKII/ERK	
VEGF ₁₆₄	Rat hippocampal	(1) Increase mEPSC	VEGFR2	21
(1 ng/ml)	neuron culture	Frequency		

fEPSP, field excitatory postsynaptic potential; PS, population spike; DG, dentate gyrus; LTP, long-term potentiation; mEPSC, miniature excitatory postsynaptic current; CaMKII, Ca2+/calmodulin-dependent protein kinase II; ERK, extracellular signal-regulated kinase; ND, not determined.

activation of the mitogen-activated protein kinase (MAPK) signaling cascade via Raf stimulation leading to gene expression and cell proliferation, activation of PI3K leading to Akt activation and cell survival, activation of phospholipase $C\gamma$ and protein kinase C leading to cell proliferation, vasopermeability and angiogenesis (8).

Beyond its well-established effects on vasculature, recent findings reveal that VEGF has multiple neurotrophic effects (10, 11). Studies involving the central nervous system (CNS) have demonstrated localization of VEGF and its receptors on neurons and astrocytes (12, 13). It has also been reported that VEGF induces neuronal outgrowth (14) and provides neuroprotection, particularly after ischemia or spinal injury (15, 16). Furthermore, VEGF has been shown to act as a neurotrophic factor to mediate the effect of enriched environment on neurogenesis and cognition (17). In addition, VEGF has been implicated in the regulation of excitatory synaptic transmission (Table 1). For instance, extracellular field potential recordings on rat hippocampal slices showed that application of exogenous VEGF₁₆₅ (200 ng/ml) decreased the evoked responses of hippocampal neurons to synaptic stimulation in each of the major glutamatergic pathways of the trisynaptic circuitry (18). In addition, $VEGF_{165}$ suppressed spontaneous discharges in hippocampal slices from pilocarpinetreated rats but has little effect on bicucullineinduced spontaneous discharges in hippocampal slices from control rats (18). McCloskey et al (19) also found that the expression of VEGF in hypoglossal motor neurons increased after seizure and application of exogenous VEGF₁₆₅ reduced depolarizing input to hypoglossal motor neurons in a brainstem slice preparation without an apparent influence on passive and active membrane properties. In contrast, a more recent study showed that a brief bath application of VEGF₁₆₅ (10 ng/ml) elicited a rapid and persistent enhancement of synaptic transmission in the hippocampal CA1 region through the activation of either Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) or extracellular signal-regulated protein kinase (ERK) signaling (20). In our recent work, using both pharmacological and genetic approaches, we have extended these findings by showing that hypoxia-inducible factor-1 α (HIF-1 α) accumulation can enhance excitatory synaptic transmission in neuron cultures hippocampal by regulating production of VEGF (21). Our results also indicate that treatment of hippocampal neuron cultures with VEGF₁₆₄ (1 ng/ ml) for 1 or 12 h elicits a significant increase in the frequency but not the amplitude of miniature excitatory postsynaptic currents (mEPSCs) and that this enhancement is blocked by the selective VEGFR-2 inhibitors or knockdown of VEGFR-2 expression by shRNA. The observed increase in mEPSC frequency by VEGF treatment is most likely attributable to an enhancement of presynaptic release probability. The lack of effect of VEGF on mEPSC kinetics also implies that its action on glutamatergic transmission is not mediated by а change in postsynaptic responsiveness to glutamate. The reasons for these discrepancies remain unclear. They may be attributable to use of different doses and time scales




Figure 1. Proposed models for the regulation of VEGF expression in neurons. Binding of IGF-1 to extracellular IGF-1 receptors triggers activation of PI3K/Akt/mTOR signaling pathway and leads to increased HIF-1 α protein expression. HIF-1 α then dimerizes with HIF-1 β to form the HIF-1 complex, which in turn translocates into the nucleus and binds to hypoxia response elements of the VEGF genes to activate transcription. Ubiquitin-dependent HIF-1 α degradation is inhibited under hypoxic condition, leading to accumulation and translocation from cytoplasm to nucleus to induce transcriptional activation of the VEGF genes. The NF- κ B activation pathway may play an adjuvant role in positive regulation of VEGF transcription. Growth factors or cytokines may activate PI3K/Akt or Ras/Raf/MEK/ERK signaling cascades, resulting in increased NF- κ B activation that upregulates VEGF gene transcription. Activated Akt may increase IkB phosphorylation and promotes its degradation, which in turn increases the release of NF- κ B from IkB and allows the activated NF- κ B to enter the nucleus and ultimately promote VEGF gene transcription.

of VEGF challenges, leading to activation of different cellular events that vary in mode of action. Further studies would be necessary to explore this conflict issue.

VEGF expression has been localized to subpopulations of neurons in the developing and mature CNS (22-24). VEGF gene and protein expression is increased in both glial cells and neurons of the ischemic brain (25). Moreover, use of an in vitro culture model demonstrates that neuronal VEGF expression is hypoxia-inducible (26). Hypoxia-inducible factor-1 (HIF-1), consisting of HIF-1 α and HIF-1 β subunit, is a dominant transcriptional factor to regulate VEGF expression in the neural cells. HIF-1 α is primarily regulated at the level of protein stability. HIF-1 α protein is rapidly degraded by the ubiquitin-proteosome system under normoxic conditions (27, 28). HIF-1 α degradation is inhibited under hypoxic conditions, leading to accumulation and translocation from cytoplasm to nucleus, where it dimerizes with HIF-16 to form the transcriptionally active HIF-1 complex (29). The activated HIF-1 complex binds to specific hypoxia response elements (HREs) of target genes and associates with transcriptional coactivators to induce gene expression (30). While HIF-1 α is regulated mainly by oxygen tension, it is noteworthy that HIF-1a is also regulated by oxygenindependent mechanisms. For example, HIF-1 α has been shown to be activated in response to insulinlike growth factor-1 (IGF-1) in cancer cells and epithelial cell lines, leading to VEGF transcription (31, 32). Previous study has also reported that activation of HIF-1 α in the CNS is involved in the mechanism by which IGF-1 promotes cell survival after cerebral ischemia (33). Our recent study has indicated that IGF-1 increases expression of HIF-1 α through activation of the PI3K/Akt/mammalian

target of the rapamycin (mTOR) signaling pathway and leads to increased VEGF secretion in hippocampal culture neurons (Figure 1) (21). Another transcription factor that may play a role in positive regulation of VEGF transcription is NF- κ B. Many growth factors and cytokines have been shown to induce transcription of the VEGF gene through NF- κ B binding to the VEGF promoter in cancer cells (34) and endothelial cells (35). However, the role of NF- κ B in transcriptional regulation of VEGF in neurons remains to be elucidated.

Despite the clear significance of the role of VEGF in regulating excitatory synaptic transmission, a recent study showed that VEGF application prior to high-frequency stimulation of hippocampal neurons increases the induction of long-term potentiation (20), a putative cellular mechanism underlying learning and memory. In addition, there is strong evidence that neuronal VEGF has an additional role in linking hippocampal activity with neurogenesis, learning and memory (17). Consistent with idea that VEGF promotes synaptic plasticity and boosts memory, transgenic mice engineered to overexpress VEGF or virus-mediated VEGF gene transfer rats have been shown to perform better in associative and spatial memory tasks (17, 36). In addition, intrahippocampal administration of VEGFR-2 antagonists following spatial training impairs longterm memory (37). Moreover, pharmacological stabilization of HIF-1a expression by application of prolyl-hydroxylase inhibitors results in the elevation of VEGF concentration in the hippocampus and contributes to a long-lasting improvement of hippocampus-dependent memory performance (38). Taken together, these findings support a role for VEGF-mediated signaling in long-term memory. VEGF expression in the hippocampus is also considered important for mediating some of the behavioral effects of antidepressants (39).

Acknowledgements

This work was supported by research grants from the National Health Research Institute (NHRI-EX99-9618NI) and from the National Science Council (NSC98-2321-B-006-001), Taiwan.

Conflicts of Interest

No potential conflicts of interest to disclose.

References

1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.

2. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46.

3. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor *in vivo*. Br J Pharmacol 1993;109:195-9.

4. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.

5. Matsunaga Y, Yamazaki Y, Suzuki H, et al. VEGF-A and VEGF-F evoke distinct changes in vascular ultrastructure. Biochem Biophys Res Commun 2009;379:872-5.

6. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65.

7. Zachary I. Neuroprotective role of vascular endothelial growth factor: signaling mechanisms, biological function, and therapeutic potential. Neurosignals 2005;14:207-21.

8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.

9. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59-83.

10. Carmeliet P, Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 2002;13:39-53.

11. Ruiz de Almodovar C, Lambrechts D, Mazzone M, et al. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009;89:607-48.

12. Kovács Z, Ikezaki K, Samoto K, et al. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 1996;27:1865-72.

13. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A 1998;95:15809-14.

14. Rosenstein JM, Mani N, Khaibullina A, et al. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 2003;23:11036-44.

15. Krum JM, Khaibullina A. Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp Neurol 2003;181:241-57.

16. Widenfalk J, Lipson A, Jubran M, et al. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience 2003;120:951-60. 17. Cao L, Jiao X, Zuzga DS, et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet. 2004;36:827-35.

18. McCloskey DP, Croll SD, Scharfman HE. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J Neurosci 2005;25:8889-97.

19. McCloskey DP, Hintz TM, Scharfman HE. Modulation of vascular endothelial growth factor (VEGF) expression in motor neurons and its electrophysiological effects. Brain Res Bull 2008;76:36-44.

20. Kim BW, Choi M, Kim YS, et al. Vascular endothelial growth factor (VEGF) signaling regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of rapamycin. Cell Signal 2008;20:714-25.

21. Huang YF, Yang CH, Huang CC, et al. Pharmacological and genetic accumulation of hypoxiainducible factor- 1α enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor. J Neurosci 2010;30:6080-93.

22. Hayashi T, Abe K, Suzuki H, Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 1997;28:2039-44.

23. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in *in vitro* ischemia. Proc Natl Acad Sci U S A 2000;97:10242-7.

24. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000;12:4243-54.

25. Lennmyr F, Ata KA, Funa K, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J Neuropathol Exp Neurol 1998;57:874-82.

26. Ogunshola OO, Antic A, Donoghue MJ, et al. Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system. J Biol Chem 2002;277:11410-5.

27. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1 α) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-7.

28. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004;5:437-48.

29. Kallio PJ, Pongratz I, Gradin K, et al. Activation of hypoxia-inducible factor 1α : posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A 1997;94:5667-72.

30. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-61.

31. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor 1. Diabetes 1997;46:1619-26.

32. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.

33. Chavez JC, LaManna JC. Activation of hypoxiainducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. J Neurosci 2002;22:8922-31.

34. Gonzalez-Perez RR, Xu Y, Guo S, et al. Leptin upregulates VEGF in breast cancer via canonic and noncanonical signaling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010;22:1350-62.

35. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009;284:6038-42.

36. Plaschke K, Staub J, Ernst E, et al. VEGF overexpression improves mice cognitive abilities after unilateral common carotid artery occlusion. Exp Neurol 2008;214:285-92.

37. Pati S, Orsi SA, Moore AN, et al. Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory. Brain Res 2009;1256:85-91.

38. Adamcio B, Sperling S, Hagemeyer N, et al. Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav Brain Res 2010;208:80-4.

39. Lee JS, Jang DJ, Lee N, et al. Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J Neurosci 2009;29:8493-505.